Department of Radiotherapy, Léon Bérard Cancer Center, Lyon, France.
Methodology and Biostatistics Unit, Centre Georges François Leclerc, Dijon, France.
Radiat Oncol. 2020 Apr 17;15(1):82. doi: 10.1186/s13014-020-01517-3.
Hypofractionated stereotactic radiotherapy (HFSRT) is indicated for large brain metastases (BM) or proximity to critical organs (brainstem, chiasm, optic nerves, hippocampus). The primary aim of this study was to assess factors influencing BM local control after HFSRT. Then the effect of surgery plus HFSRT was compared with exclusive HFSRT on oncologic outcomes, including overall survival.
Retrospective study conducted in Léon Bérard Cancer Center, included patients over 18 years-old with BM, secondary to a tumor proven by histology and treated by HFSRT alone or after surgery. Three different dose-fractionation schedules were compared: 27 Gy (3 × 9 Gy), 30 Gy (5 × 6 Gy) and 35 Gy (5 × 7 Gy), prescribed on isodose 80%. Primary endpoint were local control (LC). Secondary endpoints were overall survival (OS) and radionecrosis (RN) rate.
A total of 389 patients and 400 BM with regular MRI follow-up were analyzed. There was no statistical difference between the different dose-fractionations. On multivariate analysis, surgery (p = 0.049) and size (< 2.5 cm) (p = 0.01) were independent factors improving LC. The 12 months LC was 87.02% in the group Surgery plus HFSRT group vs 73.53% at 12 months in the group HFSRT. OS was 61.43% at 12 months in the group Surgery plus HFSRT group vs 50.13% at 12 months in the group HFSRT (p < 0.0085). Prior surgery (OR = 1.86; p = 0.0028) and sex (OR = 1.4; p = 0.0139) control of primary tumor (OR = 0.671, p = 0.0069) and KPS < 70 (OR = 0.769, p = 0.0094) were independently predictive of OS. The RN rate was 5% and all patients concerned were symptomatic.
This study suggests that HFSRT is an efficient and well-tolerated treatment. The optimal dose-fractionation remains difficult to determine. Smaller size and surgery are correlated to LC. These results evidence the importance of surgery for larger BM (> 2.5 cm) with a poorer prognosis. Multidisciplinary committees and prospective studies are necessary to validate these observations.
立体定向放射治疗(SRS)适用于大的脑转移瘤(BM)或靠近关键器官(脑干、视交叉、视神经、海马体)的情况。本研究的主要目的是评估 SRS 后影响 BM 局部控制的因素。然后比较手术加 SRS 与单纯 SRS 在肿瘤学结果(包括总生存率)方面的效果。
这是一项在莱昂·贝拉德癌症中心进行的回顾性研究,纳入了经组织学证实的 BM 患者,这些患者接受了单独的 SRS 或手术后的 SRS 治疗。比较了三种不同的剂量分割方案:27Gy(3×9Gy)、30Gy(5×6Gy)和 35Gy(5×7Gy),在等剂量 80%处规定。主要终点是局部控制(LC)。次要终点是总生存率(OS)和放射性坏死(RN)发生率。
共分析了 389 名患者和 400 个 BM,均进行了常规 MRI 随访。不同剂量分割之间无统计学差异。多变量分析显示,手术(p=0.049)和大小(<2.5cm)(p=0.01)是改善 LC 的独立因素。手术加 SRS 组 12 个月 LC 为 87.02%,SRS 组 12 个月 LC 为 73.53%。手术加 SRS 组 12 个月 OS 为 61.43%,SRS 组 12 个月 OS 为 50.13%(p<0.0085)。术前手术(OR=1.86;p=0.0028)和性别(OR=1.4;p=0.0139)、原发性肿瘤的控制(OR=0.671,p=0.0069)和 KPS<70(OR=0.769,p=0.0094)是 OS 的独立预测因素。RN 发生率为 5%,所有受影响的患者均有症状。
本研究表明 SRS 是一种有效且耐受良好的治疗方法。最佳剂量分割仍然难以确定。较小的体积和手术与 LC 相关。这些结果证明了手术对于较大的 BM(>2.5cm)和预后较差的患者的重要性。需要多学科委员会和前瞻性研究来验证这些观察结果。